Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 210 results found since Jan 2013.
Analysis of two non-pharmacological pain management methods for vaccine injection pain in infants: A randomized controlled trial
CONCLUSION: Local cold and heat application methods applied to the vaccination area before a pneumoccal vaccine reduced vaccine-associated pain in the infants, and the application of cold was more effective than heat.PMID:34254654 | DOI:10.14744/agri.2020.54289
Source: Agri Dergisi - July 13, 2021 Category: Anesthesiology Authors: Tu ğba Güngör Özlem Öztürk Şahin Source Type: research
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months
CONCLUSION: Protective hSBA titers initially declined but were retained by many subjects for 4 years irrespective of primary MenB-FHbp vaccination schedule. Boosting at 48 months after primary vaccination was safe, well tolerated, and induced immune responses indicative of immunological memory that persisted through 26 months. Booster vaccination during late adolescence may prolong protection against MenB disease.PMID:34215452 | DOI:10.1016/j.vaccine.2021.06.005
Source: Vaccine - July 3, 2021 Category: Allergy & Immunology Authors: Lars Østergaard Timo Vesikari Shelly D Senders Carl-Erik Flodmark Pavel Kosina Han-Qing Jiang Jason D Maguire Judith Absalon Kathrin U Jansen Shannon L Harris Roger Maansson Paul Balmer Johannes Beeslaar John L Perez Source Type: research
IJERPH, Vol. 18, Pages 3607: A Longitudinal Study Regarding the Health Profile of the 2017 South African Hajj Pilgrims
Conclusion: Our study indicates that a sizable proportion of South African pilgrims are elderly with underlying health conditions and most contract respiratory tract infections during and post Hajj. Our study highlights the need for systematic collection of prospective pilgrims’ demographics and health data and more attention to post-Hajj health follow-ups of pilgrims.
Source: International Journal of Environmental Research and Public Health - March 31, 2021 Category: Environmental Health Authors: Abdulaziz Mushi Yara Yassin Anas Khan Badriah Alotaibi Salim Parker Ozayr Mahomed Saber Yezli Tags: Article Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research
